The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats

por Pentel, Paul R., Raleigh, Michael D., LeSage, Mark G., Thisted, Thomas, Horrigan, Stephen, Biesova, Zuzana, Kalnik, Matthew W.
Publicado 2018

Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction

por Thisted, Thomas, Biesova, Zuzana, Walmacq, Celine, Stone, Everett, Rodnick-Smith, Max, Ahmed, Shaheda S., Horrigan, Stephen K., Van Engelen, Bo, Reed, Charles, Kalnik, Matthew W.
Publicado 2019

The efficacy and safety of a nicotine conjugate vaccine (NicVAX(®)) or placebo co-administered with varenicline (Champix(®)) for smoking cessation: study protocol of a phase IIb, d...

por Hoogsteder, Philippe HJ, Kotz, Daniel, van Spiegel, Paul I, Viechtbauer, Wolfgang, Brauer, Ruth, Kessler, Paul D, Kalnik, Matthew W, Fahim, Raafat EF, van Schayck, Onno CP
Publicado 2012

Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies

por Raleigh, Michael D., Beltraminelli, Nicola, Fallot, Stephanie, LeSage, Mark G., Saykao, Amy, Pentel, Paul R., Fuller, Steve, Thisted, Thomas, Biesova, Zuzanna, Horrigan, Stephen, Sampey, Darryl, Zhou, Bin, Kalnik, Matthew W.
Publicado 2021

Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic

por Hatsukami, Dorothy K., Jorenby, Douglas E., Gonzales, David, Rigotti, Nancy A., Glover, Elbert D., Oncken, Cheryl A., Tashkin, Donald P., Reus, Victor I., Akhavain, Roxanne C., Fahim, Raafat E.F., Kessler, Paul D., Niknian, Minoo, Kalnik, Matthew W., Rennard, Stephen I.
Publicado 2011